Eli Lilly
VC Fund
Indianapolis, United States
Eli Lilly is a VC fund in Indianapolis focused on Biotechnology and Health Care. Eli Lilly engages in the discovery, development, manufacture, and sale of products in the pharmaceutical products business segment. The company manufactures and distributes products through owned or leased facilities in the United States, Puerto Rico, and 25 other countries. Its products are sold in approximately 135 countries. It also conductsresearch to find products to treat diseases in animals and to increase the efficiency of animal food production.
- Total investments:
- 140
- Last investment:
- Lead investor:
- 24%
Last updated:
For AI agents: llms.txt
Industries Eli Lilly invests in
Stages Eli Lilly invests in
Countries Eli Lilly invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $7M–$94M
- Series B
- $6.5M–$150M
Investment Focus
Industry
- Biotechnology 89 (64%)
- Health Care 50 (36%)
- Medical 35 (25%)
- Therapeutics 32 (23%)
- Pharmaceutical 28 (20%)
Stage
- Series A 43 (31%)
- Series B 29 (21%)
- Funding Round 12 (9%)
- Series C 10 (7%)
- Seed 8 (6%)
Country
- United States 79 (56%)
- United Kingdom 12 (9%)
- Canada 3 (2%)
- China 2 (1%)
- France 2 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Barton Peterson
Senior Vice President, Corporate Affairs & Communications
|
Senior Vice President, Corporate Affairs & Communications | Total investments: 0 | Find email | |
|
Bill Ringo
President
|
President | Total investments: 0 | Find email | |
Daniel Skovronsky
Senior Vice President, and Chief Scientific Officer
|
Senior Vice President, and Chief Scientific Officer | Total investments: 0 | Find email | |
Dr Eddie Guzdar
Senior Medical Director - Immunology Northern Europe
|
Senior Medical Director - Immunology Northern Europe | Total investments: 0 | Find email | |
Eric Dozier
SVP, Human Resources, and Diversity
|
SVP, Human Resources, and Diversity | Total investments: 0 | Find email | |
| See all 14 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Remedium Bio
|
Remedium Bio is a Boston area gene therapy company focused on the development of curative treatments for a number of highly debilitating conditions. Our fundamental approach to product development utilizes proven technologies in novel ways to treat well-characterized disease pathology. To streamline R&D, we modularly apply elements of proventechnology to develop local, targeted treatments focusing on clinically validated molecules and mechanistic pathways. Today, our leading candidates include gene therapy treatments in the fields of Rheumatology / Osteoarthritis, Endocrinology / Diabetes, and Neurology / Stroke. | $10M / Series A / Aug 10, 2026 | |
Ratio Therapeutics
|
Ratio Therapeutics develops radiotherapeutics for the treatment of cancers. They engaged in research and development platforms, trillium and macropa, enable the imaging, discovery, and advancement of radiopharmaceuticals. It enables doctors to detect a wide range of epithelial-derived cancers, such as breast, pancreatic, lung, colon cancers, andmore. | $70M / Series C / Jul 31, 2026 | |
Oura
|
Oura develops a smart ring that collects data on various biometrics to support health and wellness. The device tracks sleep, readiness, and activity levels, which users can monitor through the Oura app. It employs sensors to measure heart rate, sleep cycles, and overall activity. The company operates in the health and wellness industry. | Corporate Round / Jul 15, 2026 | |
Flare Therapeutics
|
Flare Therapeutics is a biotechnology company opening up a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of its scientific founders, Flare’s team has uncovered ‘switch sites,’ druggable regions that are key targets fortranscription factor regulation to address mutations that cause disease. Its drug discovery to target switch sites has rapidly advanced, resulting in an emerging pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology with future potential in neurology, rare genetic disorders, immunology, and inflammation. | $85M / Series C / Jun 30, 2026 | |
Lycia Therapeutics
|
Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras. The company was founded by Carolyn R. Bertozzi in 2019 and is based in San Diego, California, USA. | $75M / Series D / Jun 25, 2026 | |
ProQR Therapeutics
|
ProQR Therapeutics is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa. The company's main product candidates are QR-010, QR-110, and QR-313. Its product pipelineincludes QRX-704, QRX-504, QRX-421, QRX-323 etc. | $59.2M / Post-IPO Equity / Jun 25, 2026 | |
Absci
|
Absci is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. We built our Integrated Drug Creation™ Platform to identify novel drug targets, discover optimal biotherapeutic candidates, and generate the cell lines to manufacture them in a single efficient process.Biotech and pharma innovators partner with us to create the next generation of protein-based drugs, including Bionic Proteins™ containing nonstandard amino acids, and other novel drug designs that may be impossible to make with other technologies. Our goal is to enable the development of better medicines by Translating Ideas into Drugs™. For more information visit www.absci.com. | $100M / Post-IPO Equity / Jun 24, 2026 | |
TRIMTECH Therapeutics
|
TRIMTECH Therapeutics is a biotech organization that treats neurodegenerative illnesses by using targeted protein degradation (TPD). | $14M / Seed / Jun 23, 2026 | |
Sangamo Therapeutics
|
Sangamo Therapeutics is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The company's product pipeline includes Hemophilia, Central Nervous System, HIV, LysosomalStorage Disorders, and Hemoglobinopathies. | Post-IPO Debt / Jun 23, 2026 | |
Abridge
|
Abridge provides an AI platform that transforms patient-clinician conversations into structured, billable clinical notes. This technology aims to reduce documentation burdens for clinicians and nurses. The system integrates into existing healthcare workflows and electronic health record systems. | Corporate Round / Jun 11, 2026 | |
| See all 140 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Eli Lilly invest in?
Eli Lilly invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 140 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Eli Lilly's check size?
Eli Lilly typically joins rounds of $7M–$94M at Series A and $6.5M–$150M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Eli Lilly participates in.
How do I contact Eli Lilly?
Public channels for Eli Lilly include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Eli Lilly?
The team at Eli Lilly includes Barton Peterson (Senior Vice President, Corporate Affairs & Communications), Bill Ringo (President) and Daniel Skovronsky (Senior Vice President, and Chief Scientific Officer), among 14 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
